Related Experiment Video
Updated: Jun 9, 2026

Safety Precautions and Operating Procedures in an (A)BSL-4 Laboratory: 3. Aerobiology
Published on: October 3, 2016
Addressing Biosecurity Barriers in High-Risk Biological Research
David R Gillum1, Randy A Albrecht1, Rebecca Caruso1
1David R. Gillum, PhD, is Associate Vice President, Compliance and Research Administration, University of Nevada, Reno, and Co-Founder, Tutela Strategies, LLC.; both in Reno, NV. Randy A. Albrecht, PhD, is Senior Director, Biosafety, Icahn School of Medicine at Mount Sinai, New York, NY. Rebecca Caruso, MPH, is Director, Committee on Microbiological Safety, Office of Biological Safety, Harvard Medical School, Boston, MA. Amanda Craigen is Biological Safety Officer, Environmental Health and Safety, University of North Carolina, Chapel Hill, NC. Lesley Decker, MS, is a Biosafety Manager, Environmental Health and Safety, University of Washington, Seattle, WA. Haley L. DeMers, PhD, is Director, BSL-3 Training Program, University of California, Irvine, Irvine, CA. Colleen Driskill is Director of Biosafety and Select Agent Responsible Official, University of Massachusetts Chan Medical School, Worcester, MA. Robert Foreman, PhD, is Biosafety Officer, Research Safety, Northwestern University, Chicago, IL. Deborah Howard, MPH, Expert, Global Environment, Environment Health and Safety, BASF Corporation, Durham, NC. Barbara Johnson, PhD, is Owner, Biosafety Biosecurity International, Merritt Island, FL. Jens H. Kuhn, PhD, is Principal Scientist and Director of Virology (Tunnell Government Services Contractor), Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD. Yong-Bee Lim, PhD, is Associate Director, Global Risk, Federation of American Scientists, Washington, DC. Rebecca L. Moritz, MS, is Co-Founder, Tutela Strategies, LLC, Reno, NV. Corrie Ntiforo, MSPH, is Director, Department of Biosafety, University of Texas Medical Branch; Galveston, TX. Luis Alberto Ochoa Carrera is High-Containment Lab and Pandemic Safety Manager, Environmental Health and Safety Office, Michigan State University, Lansing, MI. Gregory Park, PhD, is Director, Office of Biotechnology Activities Oversight, University of Minnesota, Minneapolis, MN. Christina L. Pier, MS, is a Select Agent Responsible Official, Environment, Health, and Safety, University of Wisconsin, Madison, WI. Antony Schwartz, PhD, is Director, Biological Safety Division, Occupational and Environmental Safety Office, Duke University, Durham, NC. Adrian Self is Operations Research Analyst, National Agricultural Biosecurity Center, Kansas State University, Manhattan, KS. Megan Shoff, PhD, is Institutional Biosafety Program Manager and Animal Biological Safety Officer, Research Compliance and Biosafety, Texas A&M University, College Station, TX. Paul Skoglund, PhD, is Institutional Biosafety Committee Coordinator, Environmental Health and Safety, University of Virginia, Charlottesville, VA. Mary Turlington-Powell, MS, Director, Biosafety and Biosecurity, and Kathleen M. Vogel, PhD, is Associate Dean and Professor, School for the Future of Innovation in Society, College of Global Futures; both at Arizona State University, Tempe, AZ. Hsiang-Ming Wang, PhD, is Director, Environmental Health and Safety, Texas Biomedical Research Institute, San Antonio, TX.
Biological research faces increasing regulatory hurdles that may hinder pandemic preparedness. Experts recommend integrating biosafety expertise into policy and ensuring consistent funding to balance risk reduction with scientific advancement.
Area of Science:
- Life Sciences
- Biosecurity
- Public Health
Background:
- Biological research, particularly concerning dual-use research and high-consequence pathogens, is under significant regulatory scrutiny.
- This scrutiny may impede pandemic preparedness efforts and slow scientific progress in biotechnology.
Purpose of the Study:
- To identify barriers to effective governance in biological research.
- To propose actionable strategies for balancing biosafety, biosecurity, and scientific advancement.
Main Methods:
- A deliberative workshop was held in Reno, Nevada, in 2024.
- Participants included biosafety professionals, biosecurity experts, and life sciences researchers.
- Discussions focused on regulatory challenges and potential solutions.
Main Results:
- Key barriers identified include ambiguous regulatory definitions, resource disparities among institutions, and fragmented oversight.
- Current frameworks may impose burdens without demonstrably improving safety or security.
- A need for collaborative dialogue and consistent funding was highlighted.
Conclusions:
- Effective governance requires incorporating biosafety expertise into policymaking.
- Shifting from punitive enforcement to collaborative dialogue is crucial.
- Sustained funding for biosecurity programs is essential for reducing risk and fostering innovation.
More Related Videos
Related Concept Videos
Biological Methods for Microbial Control
Infection
The chain begins with pathogens: bacteria, viruses, fungi, prions, or parasites such as protozoa helminths. These can be present on the skin as transient or resident flora, or they can be acquired from the environment. Identifying and treating the type of infection and...
Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
Production of Biopesticides

